A new blood-based test to screen for biomarkers of glioblastoma brain cancer has been developed by researchers at Penn State. The test looks for elevated levels of IL13Rα2, an antigen receptor that is derived from glioblastoma tumors.
Combining brain imaging data with machine learning, researchers make new discoveries about how the brain controls the hand. The findings could lead to the development of more advanced neuroprosthetics. from Neuroscience News https://ift.tt/3tv7BbC
Comments
Post a Comment